Fatigue Affects 42% of People With Multiple Gut-Brain Disorders, Global Study Finds

Fatigue is not simply a side effect of poor sleep or a bad week. For tens of millions of people living with disorders of gut-brain interaction, it is a persistent, measurable burden that scales with every additional diagnosis they carry. A new analysis published in Alimentary Pharmacology & Therapeutics draws on one of the largest gut-health surveys ever conducted to put hard numbers on that burden, and the results are striking.

Fatigue Prevalence Jumps With Each Added Gut-Brain Disorder

Veldman and colleagues drew on data from the Rome Foundation Global Epidemiology Study, an internet-based survey conducted across 26 countries using the Rome IV Adult Diagnostic Questionnaire. The final sample included 54,127 participants, 49% female, with a mean age of 44 years. Researchers split them into three groups: no disorder of gut-brain interaction (DGBI), one DGBI, and multiple DGBIs.

The gradient was unmistakable. Using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS), fatigue prevalence was 7.7% in people with no DGBI, 16.4% in those with one, and 30.2% in those with multiple diagnoses. A second measure, the Patient Health Questionnaire-12 (PHQ-12), told a similar story: 12.6% in the no-DGBI group, 25.8% in the single-DGBI group, and 42.0% in people carrying multiple diagnoses. In other words, fatigue rates more than tripled between no diagnosis and multiple diagnoses depending on which tool you use.

Two specific conditions stood out at the top of the severity ladder. Reflux hypersensitivity, a condition in which the esophagus reacts abnormally to normal acid exposure, carried the highest fatigue rates of any single diagnosis: 46% by PROMIS and 58% by PHQ-12. Irritable bowel syndrome (IBS) was close behind at 39% and 53%, respectively.

Why This Matters for Patients Dismissed as 'Just Anxious'

DGBIs affect an estimated 30 to 40% of the general population worldwide, and they are frequently associated with chronic pain and fatigue syndromes including fibromyalgia and chronic fatigue syndrome. Yet in clinical practice, these conditions are still often framed primarily as digestive problems. Patients presenting with profound tiredness alongside abdominal complaints can find their fatigue attributed to anxiety or poor lifestyle choices rather than recognized as part of the condition itself.

This study complicates that picture. Among participants with at least one DGBI, fatigue was consistently associated with female sex, higher body mass index, sleep disturbance, elevated anxiety and depression scores, greater somatic symptom burden, lower psychological well-being, and antidepressant use. Specific gastrointestinal symptoms, including early satiety, abdominal pain, and bloating, were also linked to fatigue. The overlap suggests that fatigue in this population is not simply a mood disorder wearing a gut-health costume; it tracks closely with the intensity and breadth of physical symptoms.

That has direct clinical implications. If a patient with IBS or reflux hypersensitivity reports severe fatigue, clinicians should take it seriously as part of the diagnostic picture rather than a secondary complaint. It also raises questions about treatment: are current interventions for DGBIs doing enough to address fatigue, or are patients being managed for their abdominal symptoms while their energy levels go untracked?

How the Rome Foundation Survey Captured a Global Sample

The Rome Foundation Global Epidemiology Study used a structured internet-based survey deployed in 26 countries, an approach that allowed for unusually broad geographic and demographic reach. Participants completed the Rome IV Adult Diagnostic Questionnaire, the current gold-standard tool for identifying functional gastrointestinal conditions by symptom pattern rather than structural abnormality. Fatigue was assessed through single items pulled from two validated patient-reported outcome tools: the PROMIS Global-10 and the PHQ-12, giving researchers two independent measures to cross-check.

The 54,127-person sample is large enough that even the confidence intervals on the prevalence estimates are narrow. For multiple DGBIs, the PROMIS fatigue rate of 30.2% carries a 95% confidence interval of 29.16 to 31.26; the PHQ-12 rate of 42.0% sits between 40.83 and 43.09. These are not noisy estimates driven by small numbers.

It is worth noting that Rome IV criteria, while offering improved diagnostic specificity, can be more restrictive than earlier versions, which means some people with clinically significant gut-brain symptoms may not have been classified as having a DGBI. The true prevalence of fatigue across this spectrum could be even higher.

Cross-Sectional Design Leaves the Chicken-and-Egg Problem Unsolved

The study's authors are candid about its central limitation: the cross-sectional design cannot establish which came first, the DGBI or the fatigue. Does the physiological disruption driving gut-brain dysfunction also generate fatigue through shared pathways involving the autonomic nervous system or hypothalamic-pituitary-adrenal axis? Or does chronic fatigue worsen gut symptoms through behavioral changes and central sensitization? The data, collected at a single point in time, cannot answer that.

Associated factors like sleep disturbance, anxiety, and depression are themselves bidirectionally linked to both fatigue and gut-brain disorders, which makes causal inference even more difficult. The logistic regression associations the study reports are informative for profiling high-risk patients, but they should not be read as causal pathways.

The internet-based sampling method, while enabling global reach, also introduces selection biases. People without internet access, those with severe illness who cannot complete surveys, and populations in lower-income countries may be underrepresented, despite the 26-country scope.

Longitudinal Studies and Targeted Fatigue Management Are the Next Steps

The authors call explicitly for longitudinal fatigue assessments in DGBI populations to map how fatigue evolves alongside symptom flares, treatment responses, and spontaneous remission. That kind of prospective data would be far more useful for clinicians trying to decide when and how to intervene on fatigue specifically.

The Rome Foundation's own working group on DGBI overlap has identified the incomplete understanding of shared pathophysiology across gut-brain conditions as a research priority, and this study adds fatigue squarely to that agenda. Meanwhile, DGBIs remain substantially under-taught in medical education, meaning clinicians may not be equipped to recognize fatigue as a core feature of these conditions even when a patient presents it clearly.

For now, the practical takeaway is straightforward: in any patient carrying multiple gut-brain diagnoses, fatigue screening should be routine. At 42% prevalence by one measure, it is not an edge-case complaint. It is the norm.